Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.
Paul Romness had over two decades of experience as a public and policy affairs expert when his daughter’s best friend’s osteosarcoma diagnosis inspired a new career trajectory.
After a year of monitoring implementation of the Inflation Reduction Act (IRA), including the first cohort of companies going through drug price negotiations at the end of last summer, a panel of CEOs ...